Skripsi
DEFINED DAILY DOSE PENGGUNAAN OBAT METFORMIN DI PUSKESMAS MERDEKA PALEMBANG
Background. Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia, requiring rational pharmacological therapy. Metformin is the first-line therapy for type 2 DM as recommended by WHO and the National Formulary. Defined Daily Dose (DDD) measurement enables a quantitative evaluation of drug use. However, studies on DDD for metformin in South Sumatra remain limited. Methode. This descriptive study used secondary data from the pharmacy department of Merdeka Puskesmas. Total sampling was applied, including all metformin prescription records from January to December 2023. The DDD values were calculated using WHO’s formula for DDD per 1000 population per day, incorporating parameters such as the number of prescriptions, average medication per prescription, drug dosage, population size, and time period. Result. The highest DDD of metformin was recorded in January (1.43 DDD/1000 population), while the lowest occurred in September (0.69 DDD/1000 population) due to limited drug stock. The annual average DDD was 1.06 DDD/1000 population per day, indicating that 1 out of 1000 individuals consumed metformin at a dose of 2 g daily throughout 2023. These results were influenced by fluctuations in drug availability and patient visits. Conclusion. The DDD of metformin at Merdeka Puskesmas showed a declining trend due to mid-year stock shortages. This study highlights the importance of effective drug stock management to support optimal DM treatment. Keywords. Diabetes Mellitus, Metformin, Defined Daily Dose, Drug Utilization, Public Health Center.
| Inventory Code | Barcode | Call Number | Location | Status |
|---|---|---|---|---|
| 2407006723 | T160394 | T1603942024 | Central Library (REFERENCE) | Available but not for loan - Not for Loan |
No other version available